Click here to let us help you today.           

    Mesothelioma Treatment
    Mesothelioma Information
    Mesothelioma Research
    Clinical Trials
    Mesothelioma Stages
    Peritoneal Mesothelioma
    Plural Mesothelioma
    Pericardial Mesothelioma
    Malignant Mesothelioma
    Benign Mesothelioma

Legal Help Center

    Treatment Centers
    Mesothelioma Survivors

M.D. Anderson


Sloan Kettering

    Nat. Library of Medicine
    Cancer Information
    Contact Us

Mesothelioma and Lung Cancer Information Center

Clinical Trials

Most medical ailments do not have a single treatment. Some patients may choose to enhance their treatments with new or innovative techniques currently under investigation.


Clinical trials are supported at many organizations such as medical centers, hospitals, universities and doctors' offices. The researcher will most probably be a doctor, an academic researcher or a specialist. The researchers compare the effect of the new treatment with standard treatment. Patient receiving the clinical treatment are in a treatment group, whereas patients receiving standard treatment or no treatment are in a "control" group. Researchers assign patients randomly to either a treatment or control group. If you do not know whether you are in the treatment group or the control group, it is known as a masked study. If neither you nor your doctor know if you are in a treatment or control group, it is known as a double masked study. This helps to ensure that the perception of the patient or doctor will not affect the study.

Each clinical trial study has specific eligibility requirements such as type and stage of disease, age group, or history of the patient. If you are interested in joining a clinical trial your doctor must contact one of the trials investigator and provide details about your medical history. The National Institute of Health and other organizations sponsor trials on various diseases and disorders.


A Phase II Trial of Induction Chemotherapy, Surgical Resection and Adjuvant External Beam Radiation for Locally Advanced Malignant Pleural Mesothelioma

Purpose :
Malignant mesothelioma is a rare form of cancer in which malignant cells are found in the sac lining the chest (pleura) or abdomen (peritoneum). Treatment for mesothelioma of the pleura may include surgery, chemotherapy, or radiation therapy, or a combination of these. There currently is no standard treatment for this type of cancer. Pleural mesothelioma is often diagnosed at an advanced stage, when surgery may not be an option.

Doctors at Memorial Sloan-Kettering want to determine if giving chemotherapy first -- "induction chemotherapy" -- using a combination of the drugs gemcitabine and cisplatin, will improve the chance of surgically removing the tumor. They will also determine if following surgery with radiation therapy will decrease the chance of the cancer returning. Computed tomography (CT) and positron emission tomography (PET) scanning will be used to determine the extent of tumor growth and to monitor its response to treatment.

Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
  • Patients must have a confirmed diagnosis of mesothelioma of the pleura.

A Double Blind, Placebo Controlled Randomized Phase II Trial of Gemcitabine and Cisplatin with Or Without the Vegf Inhibitor Bevacizumab (nsc#704865) in Patients with Malignant Mesothelioma

Purpose :
Mesothelioma is a cancer that arises in the lining of the lungs (pleura) or abdomen (peritoneum). In many cases, surgery is not possible and, in that situation, the treatment is chemotherapy.

A combination of the drugs gemcitabine and cisplatin is a commonly used chemotherapy regimen for mesothelioma. Investigators at Memorial Sloan-Kettering Cancer Center are participating in a multicenter trial to determine if adding an experimental drug called bevacizumab to this regimen is safe and beneficial in patients with advanced mesothelioma.

Another purpose of this study is to determine whether the combination of bevacizumab, gemcitabine, and cisplatin is better than chemotherapy with gemcitabine and cisplatin alone. Doctors do not yet know which of these two treatments is better. This is a randomized trial: Half of the patients will receive gemcitabine and cisplatin plus bevacizumab, while the other half will receive gemcitabine and cisplatin plus a placebo.

Bevacizumab is an experimental antitumor agent called an angiogenesis inhibitor. Angiogenesis inhibitors are believed to affect tumor cell growth by attacking the blood vessels that supply tumors with nutrition, rather than attacking the cancer cells directly. It is thought that when new blood vessels are unable to form to feed a growing tumor, the tumor may shrink. Studies in animals indicate that bevacizumab can decrease new blood vessel growth, cause tumors to decrease in size, and prevent tumors from spreading (metastasizing) in the body.

Eligibility: To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of malignant pleural or peritoneal mesothelioma that cannot be cured with surgery.
  • Patients may not have had prior anticancer chemotherapy. Patients who have had prior radiation therapy may not have received this treatment within 4 weeks of entering the study.
  • Patients may not have a history of deep vein thrombosis, pulmonary embolism, or stroke in the 6 months prior to entering the study, nor can they have involvement of a major blood vessel by the tumor.
  • Patients must be at least 18 years of age.

A Phase Ii, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous Sdx-102 for the Treatment of Patients with Mtap-Deficient Cancer

  Purpose :

Some types of cancer lack a protein called MTAP. SDX-102 (also called L-alanosine) is a new drug that may be helpful in treating patients with tumors that lack MTAP. In this phase II trial, investigators wish to evaluate the safety and effectiveness of SDX-102 in patients with MTAP-deficient cancers that have returned or progressed despite other treatments.

The types of cancers that will be included are soft-tissue sarcomas (connective tissue tumors), sarcomas of the bone, pleural mesothelioma (a tumor that arises between the lung and the chest wall), non-small cell lung cancer, and pancreatic cancer. Researchers will observe how the body gets rid of SDX-102, and determine if SDX-102 can keep a tumor from growing.

Eligibility: To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of soft-tissue sarcoma, osteosarcoma, pleural mesothelioma, non-small cell lung cancer, or pancreatic cancer that does not respond to chemotherapy or has progressed despite prior chemotherapy. Patients with mesothelioma must have disease that cannot be removed surgically. Patients with Ewing's sarcoma of the soft tissue or bone may not participate in this study.
  • Patients' cancers must lack the MTAP protein, as confirmed by testing of tumor specimens.
  • At least 4 weeks must have passed since prior chemotherapy, and patients must have recovered from any side effects of treatment.
  • Patients must not be confined to a bed or chair for more than half of their normal waking hours.
  • Patients must be age 18 or older (age 13 or older for patients with osteosarcoma).





Home  l  Mesothelioma Treatment  l  Mesothelioma Information  l  Mesothelioma Research  l  Mesothelioma Clinical Trials

Stages of Mesothelioma  l  Peritoneal Mesothelioma  l  Plural Mesothelioma  l  Pericardial Mesothelioma  l  Malignant Mesothelioma

Benign Mesothelioma  l  Symptoms of Mesothelioma  l  About Asbestosis  l  Contact Us

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Copyright 2019. All Rights Reserved. Inc.